CD274 and neoplasm: The three scoring methods included a score for PD-L1 expression in the tumor cells, which is the standard approach to evaluate an IHC marker in tumor and also used in the evaluation of PD-L1 in other solid tumors such as lung cancer; a score for PD-L1 expression in tumor-infiltrating immune cells, which was used in the Impassion130 trial; and a combined tumor cell and immune cell score, which is equivalent to the method used in the KEYNOTE-086 trial.